RBC Capital lowered the firm’s price target on Acadia Healthcare (ACHC) to $22 from $28 and keeps an Outperform rating on the shares, updating the firm’s model after the company’s Q3 results last week. Weaker Medicaid volume and increased bad debt expense was the primary driver of the company’s weaker performance and revised 2025 outlook, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare Settles $179M Securities Litigation
- Acadia Healthcare price target lowered to $27 from $29 at Guggenheim
- Acadia Healthcare’s Earnings Call: Mixed Sentiments and Strategic Moves
- Optimistic Buy Rating for Acadia Healthcare Amid Strategic Growth Initiatives
- Acadia Healthcare price target lowered to $22 from $25 at Cantor Fitzgerald